Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2021 08:39 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board

San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
March 03, 2021 08:37 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference

San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
February 03, 2021 09:09 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Participate in Investment Conferences in February

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
January 19, 2021 08:30 ET | Source: Skye Bioscience, Inc.

Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience

San Diego, Calif, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
January 15, 2021 13:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th

San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary,...
January 05, 2021 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the KCSA Cannabis Investor Conference

San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary...
December 16, 2020 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCVHS is Published in Peer-Reviewed Journal

Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma San...
December 07, 2020 08:45 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference

San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing...
September 30, 2020 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Provides Corporate Update

Renewed team and capital focused on advancing lead compound for glaucoma into human studies Ongoing development of lead compound, THCVHS, includes near-term preclinical assessments of neuroprotection...
September 03, 2020 11:39 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class...